Review
Chemistry, Medicinal
Tingting Liu, Shubin Song, Xu Wang, Jifu Hao
Summary: Breast cancer remains a challenging health issue and a top priority in biomedical research. Researchers are increasingly interested in studying breast cancer in young women. Common treatment options for breast cancer include chemotherapy, immunotherapy, hormone therapy, surgery, and radiotherapy.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Hematology
Andrew J. Shih, Tomi Jun, Andrew D. Skol, Riyue Bao, Lei Huang, Sapana Vora, Megan E. McNerney, Eric A. Hungate, Michelle M. Le Beau, Richard A. Larson, Aaron Elliott, Hsiao-Mei Lu, Robert Huether, Felicia Hernandez, Friedrich Stolzel, James M. Allan, Kenan Onel
Summary: Some patients with therapy-related myeloid neoplasms (t-MN) may have unsuspected inherited cancer predisposition syndrome (CPS). A set of clinical criteria has been proposed to identify t-MN patients with high risk of CPS (HR-CPS). Among the identified HR-CPS patients, 37% had pathogenic or likely pathogenic variants, compared to 0% in the low-risk CPS patients. These simple clinical criteria help identify t-MN patients most likely to benefit from genetic testing for inherited CPS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Tom Walsh, Suleyman Gulsuner, Ming K. Lee, Melissa A. Troester, Andrew F. Olshan, H. Shelton Earp, Charles M. Perou, Mary-Claire King
Summary: The Carolina Breast Cancer Study (CBCS) identified pathogenic variants in BRCA1, BRCA2, PALB2, or TP53 in a subset of breast cancer patients. The study found a significant association between BRCA1, BRCA2, and PALB2 with triple-negative breast cancer (TNBC) among African-American patients compared to European-American patients.
Article
Orthopedics
Elizabeth Dylke
Summary: This article discusses the measurement methods and techniques for breast cancer-related lymphoedema and evaluates and compares them. The results of the study provide effective methods for assessing patients' lymphoedema and guiding appropriate treatment measures.
JOURNAL OF PHYSIOTHERAPY
(2022)
Review
Oncology
Francesca Magnoni, Virgilio Sacchini, Paolo Veronesi, Beatrice Bianchi, Elisa Bottazzoli, Valentina Tagliaferri, Erica Mazzotta, Giulia Castelnovo, Giulia Deguidi, Elisabetta Maria Cristina Rossi, Giovanni Corso
Summary: The optimal surgical approach to hereditary breast cancer and the management of patients carrying mutations in high-penetrance genes are significant current clinical and scientific issues. Studies have shown that breast-conserving surgery is oncologically safe in BRCA carriers in terms of overall survival, despite an increased risk of ipsilateral recurrence.
Review
Nutrition & Dietetics
Zheng Qu, Qiang Liu, Xiangyi Kong, Xiangyu Wang, Zhongzhao Wang, Jing Wang, Yi Fang
Summary: Breast cancer is the most common cancer worldwide, and there is a need for new treatment approaches. Zinc is involved in regulating various processes in the human body, and abnormal zinc homeostasis can contribute to breast cancer. This review focuses on the role of zinc transporters in breast cancer pathogenesis, apoptosis, signal transduction, and potential clinical applications. The translation of zinc-related molecules and drug targets in breast cancer treatment is also discussed, providing insights for diagnosis and management.
Article
Oncology
Margaret L. McNeely, Naomi D. Dolgoy, Bolette Skjodt Rafn, Sunita Ghosh, Paula A. Ospina, Mona M. Al Onazi, Lori Radke, Mara Shular, Urve Kuusk, Marc Webster, Kristin L. Campbell, John R. Mackey
Summary: This study found that adding nighttime compression to the treatment of chronic breast cancer-related lymphedema, whether through self-applied compression bandaging or through the use of a nighttime compression system garment, significantly improved excess arm volume and quality of life. Nighttime compression was shown to be an effective self-management strategy for women with chronic breast cancer-related lymphedema.
Article
Medicine, General & Internal
Rayan Kabirian, Maria Alice Franzoi, Julie Havas, Charles Coutant, Olivier Tredan, Christelle Levy, Paul Cottu, Asma Dhaini Merimeche, Sophie Guillermet, Jean-Marc Ferrero, Sylvie Giacchetti, Thierry Petit, Florence Dalenc, Philippe Rouanet, Sibille Everhard, Anne-Laure Martin, Barbara Pistilli, Matteo Lambertini, Ines Vaz-Luis, Antonio Di Meglio
Summary: This study investigated chemotherapy-related amenorrhea (CRA) among premenopausal women with breast cancer and its association with long-term quality of life (QOL). The study found that most patients experienced CRA from 1 to 4 years after diagnosis, and persistent CRA was associated with worse QOL.
Article
Multidisciplinary Sciences
Brooke E. Wilson, Alexandra Desnoyers, Laith Al-Showbaki, Michelle B. Nadler, Eitan Amir
Summary: Disease-free survival (DFS) may not be a suitable surrogate endpoint for overall survival (OS) in all breast cancer subtypes. The occurrence of breast cancer-related events in DFS has decreased over time, while the occurrence of non-breast cancer-related events has increased. Therefore, there is limited surrogacy between DFS and OS.
SCIENTIFIC REPORTS
(2022)
Article
Surgery
Hong Bae Jeon, Ji Hyuk Jung, Sang Hee Im, Yong Bae Kim, Jee Suk Chang, Seung Yong Song, Dae Hyun Lew, Tai Suk Roh, Won Jai Lee, Dong Won Lee
Summary: This study aimed to investigate the impact of immediate breast reconstruction on the risk of breast cancer-related lymphedema. The results showed that immediate breast reconstruction can reduce the incidence of lymphedema.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2023)
Review
Oncology
Bella S. Ehrlich, Michael J. Mcneil, Linh T. D. Pham, Yichen Chen, Jocelyn Rivera, Carlos Acuna, Liz Sniderman, Firas M. Sakaan, Alejandra Mendez Aceituno, Cesar A. Villegas, Lisa M. Force, Nancy S. Bolous, Parima P. Wiphatphumiprates, Jeremy S. Slone, Angela K. Carrillo, Srinithya R. Gillipelli, Caitlyn Duffy, Anita Arias, Meenakshi Devidas, Carlos Rodriguez-Galindo, Sheena Mukkada, Asya Agulnik
Summary: This study systematically explores the burden of treatment-related mortality in children with cancer in LMICs and finds an association between country income level and treatment-related mortality.
Review
Biochemistry & Molecular Biology
Qinyu Han, Shi Qiu, Huiwen Hu, Wenjing Li, Xiangqi Li
Summary: Breast cancer is the most significant malignant tumor threatening women's lives. Caveolae family-related proteins play an important role in the occurrence and development of breast cancer, with Cav-1 being the most studied tumor suppressor, Cav-2 having dual functions, Cav-3 being less researched, and the role of Cavins proteins still unclear in breast cancer.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2023)
Article
Oncology
A. T. P. M. Brands-Appeldoorn, R. C. M. Thomma, L. Janssen, A. J. G. Maaskant-Braat, V. C. G. Tjan-Heijnen, R. M. H. Roumen
Summary: Multiple factors affecting cosmetic outcome after breast-conserving therapy were explored in this study, with radiotherapy boost being the only factor independently associated with poor cosmetic outcome. This finding can be useful for counselling in clinical practice, although further investigation is needed to create a prediction model.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ingi Min, Sung Joon Lim, Gi Jeong Cheon, Minseok Suh, Kwan Sik Seo
Summary: The study aims to compare the effectiveness of conventional stress lymphoscintigraphy (CSL) and pneumatic compression-assisted lymphoscintigraphy (PCAL). Among participants with relatively preserved lymphatic flow extent, the PCAL group showed better percentage reduction of volume compared to the CSL group. The use of IPC devices in lymphoscintigraphy can help in quantitatively describing lymphedema status and selecting appropriate treatment methods.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Multidisciplinary Sciences
Tomomi Nishimura, Nobuyuki Kakiuchi, Kenichi Yoshida, Takaki Sakurai, Tatsuki R. R. Kataoka, Eiji Kondoh, Yoshitsugu Chigusa, Masahiko Kawai, Morio Sawada, Takuya Inoue, Yasuhide Takeuchi, Hirona Maeda, Satoko Baba, Yusuke Shiozawa, Ryunosuke Saiki, Masahiro M. M. Nakagawa, Yasuhito Nannya, Yotaro Ochi, Tomonori Hirano, Tomoe Nakagawa, Yukiko Inagaki-Kawata, Kosuke Aoki, Masahiro Hirata, Kosaku Nanki, Mami Matano, Megumu Saito, Eiji Suzuki, Masahiro Takada, Masahiro Kawashima, Kosuke Kawaguchi, Kenichi Chiba, Yuichi Shiraishi, Junko Takita, Satoru Miyano, Masaki Mandai, Toshiro Sato, Kengo Takeuchi, Hironori Haga, Masakazu Toi, Seishi Ogawa
Summary: Recent studies have shown that clones carrying common cancer mutations frequently evolve in normal tissues, but we still lack knowledge about the additional driver events that occur before these clones evolve into cancer. In this study, using phylogenetic analyses, we found unique evolutionary histories in breast cancers with der(1;16), a common driver alteration. The timing of early evolutionary events was estimated and showed that both cancer and non-cancer clones evolved from a common ancestor in the patient's early 30s. Multiple independent cancer founders from non-cancer ancestors were also observed, contributing to intratumor heterogeneity. These findings provide new insights into the evolution of breast cancer.
Article
Oncology
Kelly L. Schoenbeck, Ehab Atallah, Li Lin, Kevin P. Weinfurt, Jorge Cortes, Michael W. N. Deininger, Vamsi Kota, Richard A. Larson, Michael J. Mauro, Vivian G. Oehler, Javier Pinilla-Ibarz, Jerald P. Radich, Charles A. Schiffer, Neil P. Shah, Richard T. Silver, James E. Thompson, Kathryn E. Flynn
Summary: Treatment-free remission (TFR) is an important goal for chronic myeloid leukemia (CML) patients. A study found that patients experienced improvements in social, physical, and sexual function after discontinuing tyrosine kinase inhibitor (TKI) treatment, but no significant improvement in cognitive function or interest in sexual activity. Scores worsened for patients who restarted TKI.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Hematology
Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung-Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee-Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramon Tiu, Mark J. Levis
Summary: The follow-up of the ADMIRAL trial after 2 years demonstrates that gilteritinib is a safe and effective treatment option for patients with relapsed/refractory FLT3-mutation-positive AML. Gilteritinib therapy provides superior overall survival and long-term remission compared to salvage chemotherapy, especially when used as post-HSCT maintenance.
Letter
Hematology
Carlo Gambacorti-Passerini, Franck Emmanuel Nicolini, Richard A. Larson, Andrea Aroldi, Diletta Fontana, Rocco Piazza, Philipp le Coutre, Laura Antolini, Sarit Assouline
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Zachary D. Epstein-Peterson, Andriy Derkach, Susan Geyer, Krzysztof Mrozek, Jessica Kohlschmidt, Jae H. Park, Sridevi Rajeeve, Eytan M. Stein, Yanming Zhang, Harry Iland, Lynda J. Campbell, Richard A. Larson, Xavier Poire, Bayard L. Powell, Wendy Stock, Richard M. Stone, Martin S. Tallman
Summary: In this study, a pooled analysis of ATO-treated APL patients revealed that patients with a complex karyotype had inferior event-free survival, while the presence of additional cytogenetic abnormalities did not significantly impact survival. These findings emphasize the importance of conducting full karyotypic analysis in all APL patients and highlight the need for novel treatment strategies to overcome the adverse effects of APL with a complex karyotype.
Article
Hematology
Ellen K. Ritchie, Heidi D. Klepin, Elizabeth Storrick, Brittny Major, Jennifer Le-Rademacher, Martha Wadleigh, Alison Walker, Richard A. Larson, Gail J. Roboz
Summary: Geriatric assessment (GA) can predict survival among older adults with acute myeloid leukemia (AML) treated intensively. This study evaluated the predictive utility of GA among older adults treated with low-intensity therapy, finding that comorbidity, cognition, and self-reported function were associated with survival and can be used as screening measures for older adults receiving lower-intensity AML therapies.
Article
Hematology
Stephane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Joerg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Doehner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.
Article
Hematology
Misha C. Tran, Yasmin Hasan, Amy Wang, Kamil Yenice, Julien Partouche, Wendy Stock, Richard A. Larson, Satyajit Kosuri, James L. LaBelle, Justin Kline, Peter A. Riedell, Andrew S. Artz, Ralph Weichselbaum, Michael R. Bishop, Bulent Aydogan, Hongtao Liu
Summary: Relapse after allo-SCT is a common issue, and a second SCT can be considered for treatment. The study explored the feasibility of combining IM-TMI with fludarabine and melphalan for conditioning in patients undergoing a second or greater allo-SCT. The results showed that the combination therapy was feasible and achieved favorable outcomes.
Article
Immunology
Tal Freund, Sarah K. Baxter, Tom Walsh, Hana Golan, Joseph Kapelushnik, Michal Abramsohn-Goldenberg, Shira Benor, Nadav Sarid, Ron Ram, Yifat Alcalay, Reeval Segel, Paul Renbaum, Polina Stepensky, Mary-Claire King, Troy R. Torgerson, David Hagin
Summary: Pathogenic variants in the LRBA gene can lead to diverse clinical symptoms with variable disease severity. A founder allele of the LRBA gene was found in the Georgian Jewish population and may be associated with increased susceptibility to malignancies.
JOURNAL OF CLINICAL IMMUNOLOGY
(2023)
Article
Critical Care Medicine
Nicole S. Benzoni, Kyle A. Carey, Alice F. Bewley, Jeff Klaus, Brian M. Fuller, Dana P. Edelson, Matthew M. Churpek, Sivasubramanium V. Bhavani, Patrick G. Lyons
Summary: In this study, temperature trajectory modeling identified distinct clinical subphenotypes among oncology patients with neutropenia and suspected infection, and these subphenotypes were independently associated with important outcomes.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Hematology
Andrew J. Shih, Tomi Jun, Andrew D. Skol, Riyue Bao, Lei Huang, Sapana Vora, Megan E. McNerney, Eric A. Hungate, Michelle M. Le Beau, Richard A. Larson, Aaron Elliott, Hsiao-Mei Lu, Robert Huether, Felicia Hernandez, Friedrich Stolzel, James M. Allan, Kenan Onel
Summary: Some patients with therapy-related myeloid neoplasms (t-MN) may have unsuspected inherited cancer predisposition syndrome (CPS). A set of clinical criteria has been proposed to identify t-MN patients with high risk of CPS (HR-CPS). Among the identified HR-CPS patients, 37% had pathogenic or likely pathogenic variants, compared to 0% in the low-risk CPS patients. These simple clinical criteria help identify t-MN patients most likely to benefit from genetic testing for inherited CPS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Sophie Ifrah, Timothy P. Hughes
Summary: Asciminib, a BCR-ABL1 inhibitor that works through the STAMP mechanism, has shown favorable efficacy and safety in patients with chronic myeloid leukemia in chronic phase. The ongoing ASC4FIRST trial aims to compare the effectiveness of Asciminib with investigator-selected TKIs in newly diagnosed patients with chronic myeloid leukemia.
Article
Otorhinolaryngology
Ryan J. Carlson, Tom Walsh, Jessica B. Mandell, Amal Aburayyan, Ming K. Lee, Suleyman Gulsuner, David L. Horn, Henry C. Ou, Kathleen C. Y. Sie, Lisa Mancl, Jay Rubinstein, Mary-Claire King
Summary: Most childhood-onset bilateral sensorineural hearing loss in the US is genetic. The study aimed to identify the genetic causes of hearing loss, assess its severity and progression, and evaluate cochlear implant success based on genotype. The results suggest that genetic diagnosis can now be integrated into precision medical care for childhood-onset hearing loss.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2023)
Article
Oncology
Naval G. Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam S. Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N. Tanaka, Terrence J. Bradley, Deepa Jeyakumar, Eunice S. Wang, Kendra Sweet, Hagop M. Kantarjian, Guillermo Garcia-Manero, Rami Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F. Zeidner, David A. Sallman
Summary: Magrolimab combined with azacitidine showed promising efficacy and tolerability in patients with untreated AML ineligible for intensive chemotherapy, including those with TP53 mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, GaryJ. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung-Soo Yoon, Yoshinobu Maeda, Naoko Hosono, Masahiro Onozawa, Takayasu Kato, Hee-Je Kim, Nahla Hasabou, Rishita Nuthethi, Ramon Tiu, Mark J. Levis
Summary: The ADMIRAL trial investigated the efficacy of using the FLT3 inhibitor gilteritinib as maintenance therapy after hematopoietic stem cell transplantation (HSCT) in patients with relapsed or refractory FLT3-mutated AML. The results showed that gilteritinib maintenance therapy improved survival rates and was well-tolerated in patients post-HSCT.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)